The dosage and administration schedules for Nutropin products should be individualized for each patient. Response to growth hormone (hGH or GH) therapy in pediatric patients tends to decrease with time. However, pediatric patients whose growth rate fails to increase (particularly during the first year of therapy) should be assessed for noncompliance and evaluation of other causes of growth failure, such as hypothyroidism, undernutrition, and advanced bone age.
- Dosing information for Nutropin AQ, Nutropin AQ Pen 10, and Nutropin AQ Pen 20
- Dosing information for Nutropin
- Use our GenenCalc dosing tool
- Nutropin AQ, Nutropin AQ Pen 10, and Nutropin AQ Pen 20
Please see Nutropin AQ full prescribing information.
Adult GH deficiency
- It is recommended that treatment be initiated at not more than 0.006 mg/kg/d subcutaneously injected, and may be increased to meet individual patient requirements up to a maximum of 0.025 mg/kg/d in patients under 35 years, and a maximum of 0.0125 mg/kg/d in patients over 35 years
- Dosage can be increased gradually to the recommended maximum based on clinical and biochemical response
- Sensitivity to GH treatment varies considerably among individuals
- Adults require considerably less GH than children
- Lower doses may be necessary to minimize the occurrence of adverse events in older or overweight patients
- During therapy, dosage should be decreased if required by the occurrence of side effects or excessive IGF-I levels
Pediatric GH deficiency
A weekly dosage of up to 0.3 mg/kg of body weight divided into daily SC injections is recommended. In pubertal patients, a weekly dosage of up to 0.7 mg/kg divided into daily doses may be used.
Idiopathic short stature
The recommended dose for ISS is up to 0.3 mg/kg/wk divided into daily subcutanious injections.
Chronic renal insufficiency
A weekly dosage of up to 0.35 mg/kg of body weight divided into daily subcutaneous injections is recommended. Nutropin therapy may be continued up to the time of renal transplantation. To optimize therapy for patients who require dialysis, the following guidelines for injection schedule are recommended:- Hemodialysis patients should receive their injection at night, just prior to going to sleep or at least 3 to 4 hours after hemodialysis. This helps to prevent the GH injection from causing a hematoma due to heparin exposure during dialysis.
- Continuous cycling peritoneal dialysis (CCPD) patients should receive their injection in the morning after they have completed dialysis.
- Continuous ambulatory peritoneal dialysis (CAPD) patients should receive their injection in the evening at the time of the overnight exchange.
Turner syndrome
A weekly dosage of up to 0.375 mg/kg of body weight divided into equal subcutaneous doses 3 to 7 times per week is recommended.
Nutropin
Please see Nutropin full prescribing information.
Adult GH deficiency
- It is recommended that treatment be initiated at not more than 0.006 mg/kg/d subcutaneously injected, and may be increased to meet individual patient requirements up to a maximum of 0.025 mg/kg/d in patients under 35 years, and a maximum of 0.0125 mg/kg/d in patients over 35 years
- Dosage can be increased gradually to the recommended maximum based on clinical and biochemical response
- Sensitivity to GH treatment varies considerably among individuals
- Adults require considerably less GH than children
- Lower doses may be necessary to minimize the occurrence of adverse events in older or overweight patients
- During therapy, dosage should be decreased if required by the occurrence of side effects or excessive IGF-I levels
Pediatric GH deficiency
A weekly dosage of up to 0.3 mg/kg of body weight divided into daily subcutaneous injections is recommended. In pubertal patients, a weekly dosage of up to 0.7 mg/kg divided into daily doses may be used.
Idiopathic short stature
The recommended dose for ISS is up to 0.3 mg/kg/wk divided into daily subcutaneous injections.
Chronic renal insufficiency
A weekly dosage of up to 0.35 mg/kg of body weight divided into daily subcutaneous injections is recommended. Nutropin therapy may be continued up to the time of renal transplantation. To optimize therapy for patients who require dialysis, the following guidelines for injection schedule are recommended:- Hemodialysis patients should receive their injection at night, just prior to going to sleep or at least 3 to 4 hours after hemodialysis. This helps to prevent the GH injection from causing a hematoma due to heparin exposure during dialysis.
- Continuous cycling peritoneal dialysis (CCPD) patients should receive their injection in the morning after they have completed dialysis.
- Continuous ambulatory peritoneal dialysis (CAPD) patients should receive their injection in the evening at the time of the overnight exchange.
